# Alembic Pharmaceuticals (NSE: APLLTD) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/APLLTD · Pivot · prices to 22 Oct 2026

Alembic Pharmaceuticals (NSE: APLLTD) closed at ₹785.00 on 22 Oct 2026, down 0.41% on the day. With a market capitalisation of ₹15,357 Cr, it ranks 414th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 22.9× trailing earnings, against a return on equity of 11.2% in FY25. Over the past year the share price has fallen 14.0%. Its 52-week range is ₹635.80 (23 Mar 2026) to ₹998.00 (4 Nov 2025); the last close is 21.3% below the high. Promoters held 69.87% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹785.00 |
| Market cap | ₹15,357 Cr |
| P/E (trailing) | 22.9 |
| ROE | 11.2% (FY25) |
| ROCE | 14.4% (FY25) |
| Debt to equity | 0.23 |
| 52-week high | ₹998.00 (4 Nov 2025) |
| 52-week low | ₹635.80 (23 Mar 2026) |
| 1-year return | −14.0% |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹6,672 Cr | ₹581 Cr |
| FY24 | ₹6,229 Cr | ₹617 Cr |
| FY23 | ₹5,653 Cr | ₹373 Cr |
| FY22 | ₹5,306 Cr | ₹516 Cr |
| FY21 | ₹5,393 Cr | ₹1,115 Cr |
| FY20 | ₹4,606 Cr | ₹801 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 69.87%
- Foreign institutions: 4.18%
- Domestic institutions: 15.94%
- Non-institutions: 10.01%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Onesource Specialty Pharma](https://app.pivotnow.in/stock/ONESOURCE) | ₹1,378.00 | ₹15,796 Cr | — | −1.3% |
| [Alivus Life Sciences](https://app.pivotnow.in/stock/ALIVUS) | ₹1,272.00 | ₹15,576 Cr | 27.7 | 17.2% |
| [Eris Lifesciences](https://app.pivotnow.in/stock/ERIS) | ₹1,143.60 | ₹15,537 Cr | 25.3 | 15.9% |
| [AstraZeneca Pharma India](https://app.pivotnow.in/stock/ASTRAZEN) | ₹6,056.00 | ₹15,252 Cr | 80.9 | 15.0% |
| [Syngene International](https://app.pivotnow.in/stock/SYNGENE) | ₹370.75 | ₹15,037 Cr | 47 | 6.5% |
| [Dr. Agarwal's Health Care](https://app.pivotnow.in/stock/AGARWALEYE) | ₹459.10 | ₹14,852 Cr | 100 | 6.6% |

## Questions and answers

### What is the share price of Alembic Pharmaceuticals today?

Alembic Pharmaceuticals (NSE: APLLTD) last closed at ₹785.00 on 22 Oct 2026. Its 52-week high is ₹998.00 and its 52-week low is ₹635.80.

### What is the market cap of Alembic Pharmaceuticals?

Alembic Pharmaceuticals' market capitalisation is ₹15,357 Cr (₹15,357 Cr) at the 22 Oct 2026 close, ranking 414th among the NSE companies Pivot tracks.

### What is the P/E ratio of Alembic Pharmaceuticals?

Alembic Pharmaceuticals trades at a trailing P/E of 22.9. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 47.

### What is the ROE and ROCE of Alembic Pharmaceuticals?

Return on equity was 11.2% in FY25 and return on capital employed was 14.4% in FY25 (consolidated figures).

### Is Alembic Pharmaceuticals a debt-free company?

No. Alembic Pharmaceuticals' debt-to-equity ratio was 0.23 in FY25, with total debt of ₹0 Cr.

### How has Alembic Pharmaceuticals stock performed over the last year?

Alembic Pharmaceuticals' share price has fallen 14.0% over the past year, −3.1% over three months and −7.2% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Alembic Pharmaceuticals?

As of 30 Jun 2026: promoters 69.87%, foreign institutions 4.18%, domestic institutions 15.94%, non-institutions 10.01%.

### Who are Alembic Pharmaceuticals' competitors?

The listed Pharma & Healthcare companies closest to Alembic Pharmaceuticals by market cap are Onesource Specialty Pharma, Alivus Life Sciences, Eris Lifesciences, AstraZeneca Pharma India, Syngene International and Dr. Agarwal's Health Care.

### Is Alembic Pharmaceuticals a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Alembic Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on APLLTD against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.